ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
1997, 'Association of hypercalcaemia, PTHrP expression and disease progression in a woman with primary squamous cell carcinoma of the breast.', Pathologe, pp. 317 - 319
,1997, 'Australian leukaemia study group myeloma II: A randomised trial of intensive combination chemotherapy with or without interferon in patients with myeloma.', British Journal Haematology, pp. 38 - 45
,1997, 'Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive comBination chemotherapy with or without interferon in patients with myeloma', British Journal of Haematology, pp. 38 - 45
,1997, 'Communication with cancer patients in culturally diverse Societies.', Annals of the New York Academy of Sciences, pp. 317 - 329
,1997, 'Diffuse alveolar damage following a singel adminstration of a cyclophosphamide containing chemotherapy regimen.', Australian and New Zealand Journal of Medicine, pp. 605 - 606
,1997, 'Paclitaxel as first line treatment for metastatic breast cancer.', Oncology, pp. 17 - 19
,1997, 'Prognosis of Kaposi`s sarcoma as an initial and later AIDS associated illness', Annals of Oncology, pp. 871 - 875
,1996, 'Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer', Urology, 48, pp. 957 - 962, http://dx.doi.org/10.1016/S0090-4295(96)00375-5
,1996, '5.14 HIV and Kaposi's sarcoma', Medical Journal of Australia, 164, pp. 539 - 542, http://dx.doi.org/10.5694/j.1326-5377.1996.tb122167.x
,1996, 'How HIV promotes malignancies', Medical Journal of Australia, 164, pp. 230 - 232, http://dx.doi.org/10.5694/j.1326-5377.1996.tb94147.x
,1996, 'Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi`s sarcoma', British Journal of Cancer, 73, pp. 989 - 994, http://dx.doi.org/10.1038/bjc.1996.193
,1996, 'High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma', British Journal of Haematology, 95, pp. 110 - 115, http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1868.x
,1996, 'HIV associated malignancies', Hematology Reviews and Communications, 9, pp. 275 - 283
,1996, 'Malignant pulmonary lymphoid disease: Case reports illustrating anatomical pattern of disease as a prognostic marker', Pathology, 28, pp. 20 - 24, http://dx.doi.org/10.1080/00313029600169443
,1996, 'Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma', Annals of Oncology, 7, pp. 1029 - 1036, http://dx.doi.org/10.1093/oxfordjournals.annonc.a010495
,1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142
,1995, 'Metastatic carcinoma infiltrating lung mimicking BOOP', Australasian Radiology, 39, pp. 405 - 407, http://dx.doi.org/10.1111/j.1440-1673.1995.tb00323.x
,1995, 'Bacillus Calmette-Guerein (BCG) enhances mobocyte-and lymphocyte-mediated bladder tumour cell killilng', British Journal of Cancer, 71, pp. 801 - 807, http://dx.doi.org/10.1038/bjc.1995.155
,1995, 'pulmonary chronic lymphocytic leukaemia: difficulty in establishing a tissue diagnosis', European Journal of Haematology, pp. 130 - 133
,1994, 'UNTITLED', MEDICAL JOURNAL OF AUSTRALIA, 161, pp. 638 - 638, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PT68600027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1994, 'Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine', Patient Education and Counseling, 24, pp. 261 - 266, http://dx.doi.org/10.1016/0738-3991(94)90069-8
,1994, 'HIV AIDS and cancer', Cancer Forum, 18, pp. 3 - 11
,1994, 'Sexual dysfunction in advanced HIV disease', AIDS Care, 6, pp. 105 - 107, http://dx.doi.org/10.1080/09540129408258030
,1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x
,1994, 'FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL)', AIDS, 8, pp. S46 - S46, http://dx.doi.org/10.1097/00002030-199411004-00179
,1994, 'PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS', AIDS, 8, pp. S14 - S14, http://dx.doi.org/10.1097/00002030-199411004-00054
,1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020
,1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x
,1993, 'Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients', Journal of Interferon Research, 13, pp. 349 - 357, http://dx.doi.org/10.1089/jir.1993.13.349
,1993, 'Human recombinant interferon-β
1992, 'NOVEL APPROACHES TO THE MANAGEMENT OF GYNECOLOGIC MALIGNANCIES - CHAIRMENS PREFACE - PROCEEDINGS OF A SATELLITE SYMPOSIUM HELD IN CAIRNS, AUSTRALIA, ON 22 SEPTEMBER 1991', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2, pp. 1 - 1, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992KF21500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1992, 'A phase II study of crisnatol mesylate in patients with ovarian carcinoma', Investigational New Drugs, 10, pp. 107 - 112, http://dx.doi.org/10.1007/BF00873127
,1992, 'Absence of Biological Effects of Orally Administered Interferon-β
1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746
,1992, 'EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA', Journal of Immunotherapy, 11, pp. 126 - 126, http://dx.doi.org/10.1097/00002371-199202000-00021
,1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163
,1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019
,1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5
,1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798
,1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781
,1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology: Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011
,1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521
,1989, 'REPETITIVE WEEKLY CYCLES OF INTERLEUKIN-2 - EFFECT OF OUTPATIENT TREATMENT WITH A LOWER DOSE OF INTERLEUKIN-2 ON NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED KILLER ACTIVITY', CANCER RESEARCH, 49, pp. 6832 - 6839, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1989CA66300061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061
,1989, 'Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells', Journal of the National Cancer Institute, 81, pp. 502 - 512, http://dx.doi.org/10.1093/jnci/81.7.502
,1989, 'Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen', Cancer Research, 49, pp. 2698 - 2702
,1989, 'Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy', Oncology (Switzerland), 46, pp. 105 - 108, http://dx.doi.org/10.1159/000226695
,1988, 'The doctor's dilemma (the nurse's Waterloo)', Cancer Investigation, 6, pp. 361 - 363, http://dx.doi.org/10.3109/07357908809080660
,1988, 'The role of interferon in cancer therapy: A current perspective', CA: A Cancer Journal for Clinicians, 38, pp. 258 - 277, http://dx.doi.org/10.3322/canjclin.38.5.258
,1988, 'Contributions of benzodiazepines to cancer therapy.', Cancer Invest, 6, pp. 103 - 111, http://dx.doi.org/10.3109/07357908809077033
,